World's Best Scientists 2026 revealed!
Larry M. Karnitz

Larry M. Karnitz

D-Index & Metrics

Biology and Biochemistry

D-Index
54
Citations
9847
World Ranking
15696
National Ranking
6541

Overview

Larry M. Karnitz is a researcher affiliated with the Mayo Clinic in the United States. Their work primarily spans the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. Within these broader fields, Karnitz has focused on subfields such as Molecular Biology, Oncology, Cancer Research, Reproductive Medicine, and Pulmonary and Respiratory Medicine.

Their research explores several main topics, including:

  • DNA Repair Mechanisms
  • PARP inhibition in cancer therapy
  • Ovarian cancer diagnosis and treatment
  • Cancer, Lipids, and Metabolism
  • RNA modifications and cancer
  • Mitochondrial Function and Pathology
  • CRISPR and Genetic Engineering

Karnitz has contributed to the scientific literature with multiple publications, including studies published in notable venues such as Cancer Research, bioRxiv (Cold Spring Harbor Laboratory), Clinical Cancer Research, Cell Reports Medicine, and Nature Metabolism. Their frequent publication venues include:

  • Cancer Research (6 publications)
  • bioRxiv (Cold Spring Harbor Laboratory) (2 publications)
  • Clinical Cancer Research (2 publications)
  • Cell Reports Medicine (1 publication)
  • Nature Metabolism (1 publication)

Representative recent papers authored or co-authored by Karnitz include:

  • Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer, 2021, Cell Reports Medicine
  • Enzymatic activation of pyruvate kinase increases cytosolic oxaloacetate to inhibit the Warburg effect, 2021, Nature Metabolism
  • VLX600 Disrupts Homologous Recombination and Synergizes with PARP Inhibitors and Cisplatin by Inhibiting Histone Lysine Demethylases, 2021, Molecular Cancer Therapeutics
  • Characterization of a RAD51C-silenced high-grade serous ovarian cancer model during development of PARP inhibitor resistance, 2021, NAR Cancer
  • Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma, 2021, Cancer Research

Throughout their career, Karnitz has frequently collaborated with several co-authors, including:

  • Scott H. Kaufmann (13 collaborations)
  • Xiaonan Hou (9 collaborations)
  • Catherine J. Huntoon (7 collaborations)
  • S. John Weroha (7 collaborations)
  • Arun Kanakkanthara (6 collaborations)

Best Publications

  • The Rad9–Hus1–Rad1 (9–1–1) clamp activates checkpoint signaling via TopBP1

    Sinny Delacroix;Jill M. Wagner;Masahiko Kobayashi;Ken Ichi Yamamoto

  • An Acetylation Site in the Middle Domain of Hsp90 Regulates Chaperone Function

    Bradley T. Scroggins;Kenneth Robzyk;Dongxia Wang;Monica G. Marcu

  • The radiosensitizing agent 7-hydroxystaurosporine (UCN-01) inhibits the DNA damage checkpoint kinase hChk1.

    Ericka C. Busby;Dru F. Leistritz;Robert T. Abraham;Larry M. Karnitz

  • Dial 9-1-1 for DNA damage: the Rad9-Hus1-Rad1 (9-1-1) clamp complex.

    Edgardo R. Parrilla-Castellar;Sonnet J.H. Arlander;Larry Karnitz

  • Stimulatory effects of the protein tyrosine phosphatase inhibitor, pervanadate, on T-cell activation events.

    J P Secrist;L A Burns;L Karnitz;G A Koretzky

  • Human Homologs of Schizosaccharomyces pombe Rad1, Hus1, and Rad9 Form a DNA Damage-responsive Protein Complex

    Elias Volkmer;Larry M. Karnitz

  • Ovarian Cancer-associated Mutations Disable Catalytic Activity of CDK12, a Kinase That Promotes Homologous Recombination Repair and Resistance to Cisplatin and Poly(ADP-ribose) Polymerase Inhibitors

    Poorval M. Joshi;Shari L. Sutor;Catherine J. Huntoon;Larry M. Karnitz

  • Effects of p56lck deficiency on the growth and cytolytic effector function of an interleukin-2-dependent cytotoxic T-cell line.

    Larry Karnitz;Shari L. Sutor;Toshihiko Torigoe;John C. Reed

  • T-cell antigen receptor ligation induces tyrosine phosphorylation of phospholipase C-gamma 1.

    J P Secrist;L Karnitz;R T Abraham

  • ATR Inhibition Broadly Sensitizes Ovarian Cancer Cells to Chemotherapy Independent of BRCA Status

    Catherine J. Huntoon;Karen S. Flatten;Andrea E. Wahner Hendrickson;Amelia M. Huehls

  • Hsp90 inhibition depletes Chk1 and sensitizes tumor cells to replication stress.

    Sonnet J.H. Arlander;Alex K. Eapen;Benjamin T. Vroman;Robert J. McDonald

  • Molecular Pathways: Targeting ATR in Cancer Therapy

    Larry M. Karnitz;Lee Zou

  • The Bile Acid Taurochenodeoxycholate Activates a Phosphatidylinositol 3-Kinase-dependent Survival Signaling Cascade

    Christian Rust;Larry M. Karnitz;Carlos V. Paya;Jorge Moscat

  • Reconstitution and molecular analysis of the hRad9-hHus1-hRad1 (9-1-1) DNA damage responsive checkpoint complex.

    Matthew A. Burtelow;Pia M.K. Roos-Mattjus;Matthew Rauen;Jeremy R. Babendure

  • Fc receptor stimulation of phosphatidylinositol 3-kinase in natural killer cells is associated with protein kinase C-independent granule release and cell-mediated cytotoxicity.

    Joy D. Bonnema;Larry M. Karnitz;Renee A. Schoon;Robert T. Abraham

  • Fc gamma receptor activation induces the tyrosine phosphorylation of both phospholipase C (PLC)-gamma 1 and PLC-gamma 2 in natural killer cells.

    Adrian T. Ting;Larry M. Karnitz;Renee A. Schoon;Robert T. Abraham

  • Interleukin-2 triggers a novel phosphatidylinositol 3-kinase-dependent MEK activation pathway.

    L M Karnitz;L A Burns;S L Sutor;J Blenis

  • Pharmacological abrogation of S-phase checkpoint enhances the anti-tumor activity of gemcitabine in vivo.

    David J. Matthews;F. Michael Yakes;Jason Chen;Michele Tadano

  • Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival

    Larry M. Karnitz;Karen S. Flatten;Jill M. Wagner;David Loegering

  • Heat shock protein 90 inhibition sensitizes acute myelogenous leukemia cells to cytarabine

    Ruben A. Mesa;David Loegering;Heather L. Powell;Karen Flatten

Frequent Co-Authors

Robert T. Abraham
Robert T. Abraham Pfizer (United States)
B. Douglas Smith
B. Douglas Smith Johns Hopkins University
Judith E. Karp
Judith E. Karp Johns Hopkins University
Paul J. Leibson
Paul J. Leibson Mayo Clinic
James G. Herman
James G. Herman University of Pittsburgh
Ann L. Oberg
Ann L. Oberg Mayo Clinic
Mark R. Litzow
Mark R. Litzow Mayo Clinic

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a Biology or Biochemistry degree in the USA can open doors to various online programs and promising career pathways in healthcare, research, and wellness. For those interested in advancing their nursing careers, programs like msn to dnp online no clinicals offer flexibility by removing traditional clinical requirements, making it easier for working professionals to achieve doctorate-level expertise.

If leadership in the healthcare sector interests you, consider exploring doctoral programs for healthcare administration. These degrees prepare graduates for administrative and executive roles in healthcare organizations. Alternatively, if pharmacy is your passion but you have not previously practiced, online pharmd programs for non pharmacists allow you to transition into the pharmacy field with a focus on remote learning.

For those more inclined toward sports science and physical health, the best online exercise science degree programs can offer new professional avenues in fitness, rehabilitation, and wellness coaching. Each pathway builds upon the foundational knowledge provided through Biology and Biochemistry studies, broadening your career possibilities in today’s dynamic health and science sectors.

Best Scientists Citing Larry M. Karnitz

Trending Scientists

Recently Published Articles